Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era
In the past decade, studies of innate immune activity against HIV-1 and other retroviruses have revealed a powerful array of host factors that can attack the virus at various stages of its life cycle in human and primate cells, raising the prospect that these antiviral factors could be manipulated i...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Frontiers Media
2017
|
| _version_ | 1797083398170214400 |
|---|---|
| author | Weatherley, D Boswell, M Rowland-Jones, S |
| author_facet | Weatherley, D Boswell, M Rowland-Jones, S |
| author_sort | Weatherley, D |
| collection | OXFORD |
| description | In the past decade, studies of innate immune activity against HIV-1 and other retroviruses have revealed a powerful array of host factors that can attack the virus at various stages of its life cycle in human and primate cells, raising the prospect that these antiviral factors could be manipulated in immunotherapeutic strategies for HIV infection. This has not proved straightforward: while HIV accessory genes encode proteins that subvert or destroy many of these restriction factors, others, such as human TRIM5α show limited potency against HIV-1. However, HIV-1 is much more susceptible to simian versions of TRIM5α: could this information be translated into the development of an effective gene therapy for HIV infection? Reigniting research into the restriction factor TRIM5α in the era of superior gene editing technology such as CRISPR-Cas9 presents an exciting opportunity to revisit this prospect. Copyright:. |
| first_indexed | 2024-03-07T01:41:14Z |
| format | Journal article |
| id | oxford-uuid:96e9b092-5cc2-4193-8abf-6bcea60407dd |
| institution | University of Oxford |
| last_indexed | 2024-03-07T01:41:14Z |
| publishDate | 2017 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:96e9b092-5cc2-4193-8abf-6bcea60407dd2022-03-26T23:56:10ZTargeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 eraJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:96e9b092-5cc2-4193-8abf-6bcea60407ddSymplectic Elements at OxfordFrontiers Media2017Weatherley, DBoswell, MRowland-Jones, SIn the past decade, studies of innate immune activity against HIV-1 and other retroviruses have revealed a powerful array of host factors that can attack the virus at various stages of its life cycle in human and primate cells, raising the prospect that these antiviral factors could be manipulated in immunotherapeutic strategies for HIV infection. This has not proved straightforward: while HIV accessory genes encode proteins that subvert or destroy many of these restriction factors, others, such as human TRIM5α show limited potency against HIV-1. However, HIV-1 is much more susceptible to simian versions of TRIM5α: could this information be translated into the development of an effective gene therapy for HIV infection? Reigniting research into the restriction factor TRIM5α in the era of superior gene editing technology such as CRISPR-Cas9 presents an exciting opportunity to revisit this prospect. Copyright:. |
| spellingShingle | Weatherley, D Boswell, M Rowland-Jones, S Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era |
| title | Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era |
| title_full | Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era |
| title_fullStr | Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era |
| title_full_unstemmed | Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era |
| title_short | Targeting TRIM5 alpha in HIV cure strategies for the CRISPR-Cas9 era |
| title_sort | targeting trim5 alpha in hiv cure strategies for the crispr cas9 era |
| work_keys_str_mv | AT weatherleyd targetingtrim5alphainhivcurestrategiesforthecrisprcas9era AT boswellm targetingtrim5alphainhivcurestrategiesforthecrisprcas9era AT rowlandjoness targetingtrim5alphainhivcurestrategiesforthecrisprcas9era |